Sign up to save your podcasts
Or
Share S13 Ep25: FDA Approval Insights: Darolutamide for Metastatic Castration-Sensitive Prostate Cancer: With Alicia Morgans, MD, MPH; and Neal Shore, MD, FACS
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S13 Ep25: FDA Approval Insights: Darolutamide for Metastatic Castration-Sensitive Prostate Cancer: With Alicia Morgans, MD, MPH; and Neal Shore, MD, FACS
In today’s episode, supported by Bayer, we had the pleasure of speaking with Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS, about the FDA approval of darolutamide (Nubeqa) plus androgen deprivation therapy for patients with metastatic castration-sensitive prostate cancer (mCSPC). Morgans is the medical director of the survivorship program at Dana-Farber Cancer Institute; as well as an associate professor of medicine at Harvard Medical School, both in Boston, Massachusetts. Shore is the medical director of the Carolina Urologic Research Center.
In our exclusive interview, Drs Morgans and Shore discussed the significance of this approval; key efficacy, safety, and quality of life data from the pivotal phase 3 ARANOTE trial (NCT04736199); and how this regulatory decision both opens doors for the treatment of more patients and raises questions about the optimal role of darolutamide in the management of mCSPC.
View all episodes
By OncLive® On Air
4.3
2222 ratings
In today’s episode, supported by Bayer, we had the pleasure of speaking with Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS, about the FDA approval of darolutamide (Nubeqa) plus androgen deprivation therapy for patients with metastatic castration-sensitive prostate cancer (mCSPC). Morgans is the medical director of the survivorship program at Dana-Farber Cancer Institute; as well as an associate professor of medicine at Harvard Medical School, both in Boston, Massachusetts. Shore is the medical director of the Carolina Urologic Research Center.
In our exclusive interview, Drs Morgans and Shore discussed the significance of this approval; key efficacy, safety, and quality of life data from the pivotal phase 3 ARANOTE trial (NCT04736199); and how this regulatory decision both opens doors for the treatment of more patients and raises questions about the optimal role of darolutamide in the management of mCSPC.
More shows like OncLive® On Air
View all
JAMA Editors' Summary
135 Listeners
NEJM This Week
320 Listeners
JAMA Clinical Reviews
495 Listeners
Research To Practice | Oncology Videos
115 Listeners
ASCO Daily News
57 Listeners
Core IM | Internal Medicine Podcast
1,152 Listeners
The ONS Podcast
197 Listeners
OncoPharm
186 Listeners
JAMA Medical News
89 Listeners
The Clinical Problem Solvers
513 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
363 Listeners
Oncology Today with Dr Neil Love
57 Listeners
CCO Oncology Podcast
9 Listeners
Two Onc Docs
189 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
43 Listeners